Abiraterone
Castration-Resistant Prostate Carcinoma
Explore 215 assets in Castration-Resistant Prostate Carcinoma →Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
AstraZeneca
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
61High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07641855CT.gov A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07570979CT.gov A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT07311694CT.gov A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07226986CT.gov A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC | — | Recruiting | — | — | — |
NCT06894511CT.gov An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC | — | Active Not Recruiting | — | — | — |
NCT06863272CT.gov A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) | — | Recruiting | — | — | — |
NCT06527690CT.gov Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT06632977CT.gov Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | — | Recruiting | — | — | — |
NCT06768255CT.gov Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPC | — | Not Yet Recruiting | — | — | — |
NCT06329830CT.gov 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer | — | Withdrawn | — | — | — |
Show 40 more trialsShow fewer
NCT06500247CT.gov Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer. | — | Not Yet Recruiting | — | — | — |
NCT06378866CT.gov Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial | — | Recruiting | — | — | — |
NCT05689021CT.gov CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | — | Active Not Recruiting | — | — | — |
NCT06136650CT.gov A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | — | Recruiting | — | — | — |
NCT05968599CT.gov A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT05551117CT.gov A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors | — | Terminated | — | — | — |
NCT05818683CT.gov A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05701007CT.gov Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | — | Completed | — | — | — |
NCT05393791CT.gov Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC | — | Recruiting | — | — | — |
NCT05520138CT.gov Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) | — | Completed | — | — | — |
NCT05156450CT.gov TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer | — | Unknown | — | — | — |
NCT05084859CT.gov A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04844749CT.gov Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent | — | Terminated | — | — | — |
NCT04691804CT.gov A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT04839055CT.gov The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC | — | Unknown | — | — | — |
NCT04477512CT.gov Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial) | — | Completed | — | — | — |
NCT04666129CT.gov Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT04597125CT.gov RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) | — | Active Not Recruiting | — | — | — |
NCT04296578CT.gov Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone | — | Withdrawn | — | — | — |
NCT03999515CT.gov Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04108247CT.gov A Study of Abiraterone in Combination With SHR3162 in the Treatment of mCRPC | — | Unknown | — | — | — |
NCT03896984CT.gov Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo). | — | Completed | — | — | — |
NCT03903835CT.gov ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT03748641CT.gov A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03360721CT.gov Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03431350CT.gov A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03173859CT.gov Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients | — | Withdrawn | — | — | — |
NCT03480646CT.gov ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03325127CT.gov Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study | — | Withdrawn | — | — | — |
NCT03016741CT.gov Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03012321CT.gov Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | — | Active Not Recruiting | — | — | — |
NCT02703623CT.gov Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02429193CT.gov Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA | — | Completed | — | — | — |
NCT02049190CT.gov Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | — | Unknown | — | — | — |
NCT01995058CT.gov Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | — | Terminated | — | — | — |
NCT01884285CT.gov AZD8186 First Time In Patient Ascending Dose Study | — | Completed | — | — | — |
NCT01717898CT.gov A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT01576172CT.gov Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01487863CT.gov Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Castration-Resistant Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abiraterone (this asset) | AstraZeneca | Approved | BB · 69 |
| Darolutamide | Bayer | P4 | BBB |
| Enzalutamide | Prostate Cancer Clinical Trials Consortium | P4 | BBB |
| Prednisolone | Ding-Wei Ye | P4 | BBB |
| Cabozantinib | Rana McKay, MD | P3 | BB |
| Mevrometostat | Prostate Cancer Clinical Trials Consortium | P3 | BB |
| Radium Ra-223 | University of California, San Francisco | P4 | BB |
| Prednisone | Janssen Research & Development, LLC | P4 | BB |
| Denosumab | Cancer Trials Ireland | P3 | BB |
+42 more in the Castration-Resistant Prostate Carcinoma cohort
Other indications for Abiraterone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Carcinoma | — | P4 | BBB · 72 |
| Prostate Neoplasm | — | P3 | BB · 71 |
| Metastatic Prostate Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abiraterone in Castration-Resistant Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abiraterone-castration-resistant-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →